We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current TLX market cap is 9.69B. The company's latest EPS is AUD 0.0158 and P/E is 1856.33.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 15.38M | 18.87M | 26.75M | 160.19M | 502.74M |
| Operating Income | -28.36M | -42.89M | -76.95M | -90.81M | 51.08M |
| Net Income | -27.87M | -44.89M | -80.51M | -104.08M | 5.21M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 102.61M | 157.82M | 109.81M | 255.35M | 398.3M |
| Total Liabilities | 32.53M | 78.81M | 107.66M | 175.35M | 249.39M |
| Total Equity | 70.08M | 79.02M | 2.16M | 80.01M | 148.91M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -23.33M | 1.96M | -59.33M | -63.97M | 23.88M |
| Investing | -468k | -1.09M | -2.73M | -17M | -25.49M |
| Financing | 42.72M | 34.12M | 2.85M | 174.96M | 10.19M |
| Market Cap | 9.69B |
| Price to Earnings Ratio | 1856.33 |
| Price to Sales Ratio | 19.28 |
| Price to Cash Ratio | 78.65 |
| Price to Book Ratio | 65.09 |
| Dividend Yield | - |
| Shares Outstanding | 330.45M |
| Average Volume (1 week) | 1.09M |
| Average Volume (1 Month) | 854.72k |
| 52 Week Change | 152.63% |
| 52 Week High | 29.44 |
| 52 Week Low | 10.335 |
| Spread (Intraday) | 0.15 (0.51%) |
| Company Name | Telix Pharmaceuticals Ltd |
| Address |
telix pharmaceuticals limited melbourne, victoria 3051 |
| Website | https://www.telixpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
